my personal edition > diabetes > news
E-Mail this DGReview to a colleague
DGReview
Silybin-Beta-Cyclodextrin Reduces Glucose, Triglyceride Levels In Diabetes With Liver Disease
A DGReview of :"Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent."
Diabetes, Nutrition & Metabolism: Clinical and Experimental
11/12/2002
By Mark Greener
Oral silybin-beta-cyclodextrin reduces glucose and triglyceride plasma levels in patients with type II diabetes and alcoholic liver disease.
Researchers from the University of Padova, Italy, assessed an oral formulation of the antioxidant in 60 patients with chronic alcoholic liver disease and concomitant type II diabetes. Such patients typically show raised plasma levels of glucose, insulin and triglycerides, increased lipid peroxidation and reduced innate antioxidant reserves. Forty-two patients completed six months treatment.
Fasting blood glucose levels decreased by 14.7 percent from baseline in patients receiving silybin-beta-cyclodextrin. In contrast, levels were "virtually unchanged" among placebo users. Although mean daily blood glucose levels, glycosylated haemoglobin and HOMA-IR, a measure of insulin sensitivity, also declined, the differences from baseline were not statistically significant. As basal and stimulated C-peptide values did not differ markedly between the groups, the authors commented that insulin secretion was "virtually unaffected".
Plasma triglycerides concentrations dropped from a mean 186 to 111 mg/dl at six months in those that received silybin-beta-cyclodextrin. This compared to an increase from 159 to 185 mg/dl among placebo users. The difference between the active and placebo groups was statistically significant. Malondialdehyde levels " a measure of oxidative stress " declined only in patients taking silybin-beta-cyclodextrin.
Total and HDL cholesterol did not change significantly in either group. Similarly, liver function test remained stable. No clinically relevant side effects emerged in either group.
The authors concluded that in patients with type II diabetes and compensated chronic alcoholic liver disease, oral silybin-beta-cyclodextrin reduces plasma levels of glucose and triglycerides. They speculated that these improvements might reflect the "recovery of energy substrates" arising from the decline in lipid peroxidation and enhanced insulin activity.
Diabetes Nutr Metab 2002;15:222-31.
"Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent."
All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.
| 
